INS and breast cancer: Presented an in vitro selective antitumor activity against insulin-like growth factors-dependent cell lines, such as the human breast cancer cell lines MCF-7 and T47D, with half maximal inhibitory concentration (IC50) of 9.7 ng/mL and 32 ng/mL, respectively [122].